The ratios between von Willebrand factor propeptide (VWFpp) or FVIII coagulant activity (FVIII:C) and VWF antigen (VWF:Ag) reflect synthesis, secretion and clearance of VWF. We aimed to define the pathophysiology of 658 types 1, 2 and 3 von Willebrand disease (VWD) patients with VWF levels ≤30 U/dL from the "Willebrand in the Netherlands" (WiN-)study using the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios. We also evaluated the use of VWFpp in the classification and diagnosis of VWD. Based on the ratios, reduced VWF synthesis was observed in 18% (67/380) of type 1 patients and in only 2% (5/240) of type 2 patients. A significant proportion of type 3 patients had detectable VWFpp (14/37, 41%). These patients had a lower bleeding score than type 3 patients with complete absence of both VWF:Ag and VWFpp: 14.0 vs. 19.5, p=0.025. The majority of these patients had missense mutations associated with rapid VWF clearance, whereas "true" type 3 patients were homozygous for null alleles. In conclusion, VWFpp identified severe type 1 VWD with very low VWF levels in patients who had previously been classified as type 3 VWD. This study underlines the clinical significance of the VWFpp assay in the diagnosis and classification of VWD.
Introduction
Von Willebrand factor (VWF) is a large multimeric glycoprotein that mediates platelet adhesion and aggregation at sites of vascular injury, and serves as the carrier of factor VIII (FVIII) to prevent its premature clearance [1, 2] . Synthesis of VWF is restricted to endothelial cells and megakaryocytes [3] , where it is formed as a precursor protein, pre-proVWF, with a signal peptide, a propeptide and a mature subunit [4] . After translocation to the endoplasmic reticulum the signal peptide is cleaved, and the pro-VWF undergoes extensive post-translational modifications, including dimerization in the endoplasmic reticulum and multimerization in the Golgi system [5, 6] . The VWF propeptide (VWFpp) is subsequently removed from the mature VWF, however it stays noncovalently bound [7] . Part of VWF is secreted constitutively into the plasma and the remaining part is stored in Weibel-Palade bodies in the endothelium or α-granules in megakaryocytes [8.9] . After release into the circulation, the VWFpp and the mature VWF completely dissociate [8] .
Plasma VWF concentrations represent a balance between synthesis, secretion and clearance from the circulation. VWF and VWFpp are secreted equimolarly, but are cleared independently with estimated half-lives of 8-12 hours for VWF and 2 hours for VWFpp [10, 11] . The ratio between VWFpp and VWF antigen (VWF:Ag) can therefore be used to assess the rates of synthesis, secretion and clearance of VWF [10, 12, 13] . In addition to VWFpp, the ratio between FVIII coagulant activity (FVIII:C) and VWF:Ag can also be used to assess VWF synthesis and clearance [14] . Since FVIII and VWF circulate in blood as a complex and are cleared together, their half-lives are strongly related [15] . VWF is deficient or defective in von Willebrand disease (VWD), the most com-101 chapter 6 mon inherited bleeding disorder [16, 17] . Low VWF levels are caused by reduced VWF synthesis or secretion, increased VWF clearance, or a combination thereof [18, 19] . Recently, Eikenboom et al. have shown that the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios represent the pathophysiology of VWD and correspond to different VWF gene mutations in type 1 VWD [20] . However, it is still unknown whether these ratios can also provide insight into the pathophysiological mechanism in types 2 and 3 VWD.
VWD patients are classified as type 1, 2 or 3 VWD according to their remaining level of functional VWF [16, 21] . Type 1 VWD is characterized by partially reduced VWF levels, while type 3 VWD show completely absent VWF plasma levels. In type 2 VWD, functionally abnormal variants of VWF are synthesized. Type 2 VWD is subclassified as 2A, 2B, 2M or 2N, based on the type of functional defect in VWF [16, 21] . In some patients it is difficult to classify VWD correctly, as the available diagnostic laboratory tests do not provide adequate information to distinguish between VWD (sub)types. In addition, these laboratory assays are less sensitive in measuring extremely low VWF and FVIII levels and are therefore less reliable.
In this large nationwide cross-sectional Willebrand in the Netherlands (WiN)-study, we aimed to define the pathophysiology of type 1, 2 and 3 VWD using the VWFpp/ VWF:Ag and FVIII:C/VWF:Ag ratios irrespective of the VWF gene mutation. In addition, we evaluated if the use of VWFpp can improve the diagnosis and classification of VWD.
Methods

Participants
In the nationwide cross-sectional "Willebrand in the Netherlands" (WiN-)study 804 VWD patients who had previously been diagnosed with types 1, 2 or 3 VWD, were included [23] [24] [25] . The inclusion criteria for the WiN-study were (1) hemorrhagic diathesis or a family history of VWD and (2) historically lowest VWF levels ≤30 U/dL (VW-F:Ag and/or VWF:RCo) and/or FVIII:C levels ≤40 U/dL. Patients were excluded if they were known to have other hemostatic disorders resulting in hemorrhagic diathesis. The Medical Ethical Committees at all participating centers approved this study, and all participants gave informed consent.
For the current study, only patients from whom plasma was obtained were selected (n=681). Exclusion criteria were pregnancy (n=7) and the recent use of desmopressin or replacement therapy at the time of blood sampling (n=16). Therefore, a total of 658 VWD patients were included in the current study.
Assessment of bleeding symptoms
All patients completed a questionnaire regarding bleeding episodes, treatment of VWD, co-morbidity, and Quality of Life [24] [25] [26] [27] . To calculate a bleeding score (BS), as previously described by Tosetto [28] , we used information on the severest life-time event of each of twelve specific bleeding symptoms. To avoid prophylaxis-bias, bleeding symptoms were not scored if patients had received prophylactic desmopressin or prophylactic replacement therapy before a surgical intervention, dental extraction or delivery [24, 29] . However, if bleeding did occur despite prophylactic treatment, this bleeding was scored according to the Tosetto BS.
Laboratory measurements
Patients' plasma was obtained at inclusion in the study. Venous whole blood was collected in 0.105M sodium citrate tubes and centrifuged twice at 2200x g for 10 minutes at room temperature and stored at -80°C. VWF:Ag, VWF activity (VWF:Act), FVIII:C, VWF binding to FVIII (VWF:FVIIIB), and VWF multimers were determined centrally at the Erasmus University Medical Center, Rotterdam, as described [24] . VWFpp was measured centrally at the Leiden University Medical Center, Leiden. This assay was also used in the previous paper from Eikenboom et al. [20] , and was measured at the same center. VWFpp antigen was determined with an ELISA using antibodies from Sanquin (Amsterdam, the Netherlands) as described [10, 20] . First microtiter plates were coated with antibody CLB-Pro 35 overnight at 4°C, then blocked with 1% Bovine Serum Albumin (BSA) at room temperature for 2 hours. Next the diluted samples were incubated for 2 hours at 37°C. VWFpp was detected with peroxidase-conjugated antibody CLB-Pro 14.3. Pooled normal plasma was used to create a standard curve. At the time of the study, no international standard was available for VWFpp and therefore the plasma pool was arbitrarily set at 100 U/dL. Details on the blood-sampling procedure and laboratory measurements at inclusion in the study have been described in more detail by de Wee et al [24] .
Definitions
Determination of VWD type was based on the current ISTH guidelines [16] , using centrally measured plasma concentrations of VWF:Ag, VWF:Act and FVIII:C; VWF multimer patterns; VWF:FVIIIB assay; and locally performed ristocetin-induced platelet aggregation (RIPA) tests [24] . Type 1 VWD patients had a VWF:Act/VWF:Ag ratio ≥0.70, whereas type 2 patients had a ratio <0.70. If type 2 patients had normal multimers they were classified as 2M. Type 2A or 2B VWD patients showed abnormal multimers. If the locally performed RIPA test showed increased VWF affinity for platelets, patients were classified as type 2B. Type 2N patients had a FVIII:C/VWF:Ag ratio <0.70, and VWF:FVIIIB <60%. Type 3 VWD was defined as having both VWF:Ag and VWF:Act levels <5 IU/dL, irrespective of FVIII:C level.
The normal range (2.5 th to 97.5 th percentile) used for VWFpp was 82-173 U/dL, for the VWFpp/VWF:Ag ratio 0.8-2.2, and for the FVIII:C/VWF:Ag ratio 0.6-1.9, as reported before by Eikenboom et al. [20] .
Statistical methods
Descriptive statistics for categorical data are presented as numbers with percentages (n, %). As data were non-normally distributed, continuous variables are presented as median with 25-75% interquartile ranges [IQR] . For comparison of proportions, chi-squared tests were used. The Kruskal-Wallis test was used to test differences in VWF:pp, VWFpp/VWF:Ag ratio and FVIII:C/VWF:Ag ratio between types 1, 2A, 2B, 2M, 2N and 3 VWD. Mann-Whitney U-test were applied to detect differences between types and to compare bleedings score between groups. Statistical analyses were performed with SPSS for Windows, version 21.0 (SPSS Inc, Chicago, USA). A p-value <0.05 was considered statistically significant.
Results
A total of 658 VWD patients were included in the current analyses, 381 of whom had type 1 VWD, 240 type 2 VWD, and 37 type 3 VWD, according to the current ISTH guidelines [16] . Baseline characteristics are presented in table 1. 1A and  table 2 ). This is in accordance with previously published data by Eikenboom et al. [20] . The yellow area represents the patients with increased clearance, the purple area the patients with reduced synthesis, the green area the patients with a combination of both mechanisms, and the white area represents the absence of these pathophysiological mechanisms. For a better presentation of the graphics: one type 1 VWD patient with a very high VWFpp/Ag ratio (33.7), and two type 1 VWD patients with high FVIII:C/VWF:Ag ratios (8.4 and 9.7) were omitted. B: Proportion of VWD patients with increased clearance (yellow), reduced synthesis (purple), combination of increased clearance and reduced synthesis (green), and none of these mechanisms (white). X = not present.
VWF parameters and ratios per type of VWD
Pathophysiological mechanisms in type 2 VWD variants
Based on increased VWFpp/VWF:Ag or FVIII:C/VWF:Ag ratios, the majority of type 2A VWD was characterized by an increased clearance of VWF (93/158, 59%), followed by a combination of increased clearance and reduced synthesis (50/158, 32%). In only five (of 158, 3%) patients with 2A VWD, reduced synthesis of VWF predominated. In ten (of 158, 6%) 2A patients, the VWD was characterized by neither increased clearance nor reduced synthesis. Ninety-five percent (40/42) of type 2B patients showed an increased VWFpp/VWF:Ag ratio with a normal FVIII:C/VWF:Ag ratio, suggesting that 2B VWD is completely characterized by an increased clearance of normally synthesized and secreted VWF. The pathophysiological mechanisms of type 2M VWD were an increased clearance in almost half of the patients (13/27, 48%) and a combination of increased clearance and reduced synthesis in the other half (12/27, 44%). None of the 2M patients had an increased FVIII:C/VWF:Ag ratio, indicating that 2M VWD is not characterized by reduced synthesis solely. Ten (of 14, 71%) 2N patients had an increased VWFpp/VWF:Ag ratio, indicating that apart from reduced FVIII binding the type 2N VWD is also characterized by increased clearance (Figure 2 ). [12, 18, 30, 31] . Additionally, three were compound heterozygous for a null allele and an unknown defect on the other allele.
Type 3 VWD patients
Bleeding phenotype, VWFpp and pathophysiological mechanism
Bleeding score was significantly higher in the "true" type 3 patients with undetect- (table 3) . In patients with type 1 VWD, the BS was not associated with the pathophysiological mechanisms of VWD, i.e. increased clearance, reduced synthesis, combination of increased clearance and reduced synthesis, or none of these mechanisms: median BS 10.0 vs. 9.0 vs. 8.5 vs. 9.0 respectively ( Figure 3A) . However, all type 2 patients with increased clearance, reduced synthesis or combination, had significantly higher BS than type 2 patients with none of these pathophysiologic mechanisms (p=0.010). Median BS in type 2 patients with increased clearance ( 
Discussion
In the present study from the WiN-cohort, we present as first that VWFpp improved the discrimination of true type 3 VWD patients with a total absence of both VWF:Ag and VWFpp, and VWD patients with extremely rapid VWF clearance leading to very low VWF plasma levels. Moreover, the ratios of VWF:Ag with VWFpp or FVIII:C differ between type 1 and 2 VWD. Type 2 VWD was mainly characterized by an increased clearance of VWF and type 1 VWD had a more heterogeneous pathophysiology. Finally, low VWFpp was associated with higher BS in type 3 and type 2 VWD. VWF levels, i.e. increased clearance and reduced synthesis of VWF [12, 20, 32] . We confirmed this in our study and showed that the pathophysiology of type 1 VWD is diverse, as our type 1 patients showed a mixture between VWF synthesis and clearance defects using the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios. Almost two fifth of patients did not have increased ratios. Probably VWD in these patients results from
other not yet identified mechanisms. This confirms the heterogeneity of type 1 VWD and the various causes of low VWF levels.
We hypothesized that as a result of our inclusion criteria (historically lowest VWF levels <30 U/dL), we selected more type 1 patients with accelerated clearance of VWF or reduced synthesis, and therefore patients with higher ratios. However, the VWFpp levels and ratios thereof in our type 1 patients are in agreement with a previous study in type 1 VWD patients [20] . This is remarkable as in the MCMDM-1VWD study also milder cases were included. Regression to the mean or the effect of aging on VWF and FVIII levels may have been observed [27] . We observed a higher VWFpp/VWF:Ag ratio in type 2 VWD patients compared with type 1 VWD patients. However, type 1 patients had a significantly higher FVIII:C/VW-F:Ag ratio, revealing reduced synthesis as a pathophysiological mechanism of VWD in type 1, but rarely or not in type 2 VWD. This also suggests that these ratios may discriminate between type 2 en type 1 VWD, which has been stated before [33] .
The main pathophysiological mechanism of type 2 VWD is increased VWF clearance, as the majority of type 2A, 2B and 2M patients showed an increased VWFpp/VW-F:Ag ratio. In addition, a small proportion of type 2 patients showed a combination of reduced VWF survival and reduced synthesis, but this was only seen in 2A and 2M VWD. The effect of proteolysis of VWF on clearance has been argued [3, 30, 34, 35] . We found no differences between 2A VWD with defects in multimerization and enhanced ADAMTS-13-mediated proteolysis, and 2M VWD with normal multimer patterns. Because of small sample size these findings should be interpreted with care. Our data indicate that 2B VWD is completely characterized by a normal synthesis and an increased clearance of VWF, which has been shown before in 18 type 2B VWD patients [36] . It has been suggested that the mutant VWF is cleared faster in these patients due to the spontaneous binding of VWF to platelets [17, 19, 37, 38] . Our results also showed that the mutant type 2N VWF is cleared faster than normal VWF.
To the best of our knowledge, this is the first study to assess VWFpp in VWD patients with VWF:Ag and VWF:Act <5 IU/dL, the diagnostic criteria used in the current ISTH classification for type 3 VWD [16] . We showed that VWFpp is detectable in half of the type 3 VWD patients, indicating that VWF is actually produced but very rapidly cleared from the circulation in these patients. Our findings suggest that these type 3 VWD patients should actually reclassify as severe type 1 VWD patients. We therefore conclude that VWFpp can discriminate between "true" type 3 VWD with complete absence of both VWF:Ag and VWFpp, and severe type 1 VWD with extremely low VWF levels. A significant proportion of these severely affected type 1 VWD patients had blood group O, which may have contributed to the low VWF levels in these patients. Distinguishing between true type 3 VWD and severe type 1 VWD is of clinical importance as VWD patients with lack of VWF but detectable VWFpp have different clinical characteristics than those with a complete absence of both VWF and VWFpp.
Because VWF:Ag and FVIII:C levels are associated with bleeding phenotype in VWD [24, 28, 39] , it may be expected that VWFpp also associates with bleeding phenotype in VWD patients: indirectly through its association with VWF:Ag or by binding to mature VWF in the circulation [40] . Interestingly, we found that the presence of VWFpp in patients with VWF:Ag levels <5 IU/dL correlates with a milder bleeding phenotype. We also observed that increased clearance, reduced synthesis and a combination thereof associates with higher bleeding scores in type 2 patients. [12, 18, 30] . Therefore assessing VWFpp may substitute for VWF gene analyses as it identifies carriers of two null alleles and thus "true" type 3 VWD. In addition, the MCMDM-1VWD study has recently shown that a high VWFpp/VWF:Ag ratio predicts the detection of VWF gene mutations in type 1 VWD patients [20] . Additionally, patients with mutations in regions of the VWF gene associated with reduced VWF survival, can be identified with the VWFpp/VWF:Ag ratio [12, 18, 30] . Based on our results and the current literature, we believe that measurement of VWFpp should be implemented as a standard diagnostic in VWD for patients with low VWF levels and may render mutation analysis of the VWF gene unnecessary.
VWFpp measurement is of clinical importance because its ratio with VWF:Ag predicts reduced VWF survival and may therefore predict desmopressin response. In patients with increased VWF clearance, VWF disappears rapidly after desmopressin administration. The desmopressin response in these patients is probably sufficient for hemostasis in case of minor bleeding, but inadequate in case of major bleeding or surgery because they lack a sustained response [13, 18, 42] . The FVIII:C/VWF:Ag ratio can also help in the classification of VWD patients, as those patients with an increased FVI-II:C/VWF:Ag mainly classify as type 1 VWD. With the current novel insights into the pathophysiology and molecular biology of VWD the classification of VWD should be reviewed in the near future.
In conclusion, VWFpp discriminates between true type 3 VWD patients with complete lack of VWF and severe type 1 VWD patients with very low VWF levels. An increased FVIII:C/VWF:Ag ratio may help identify type 1 VWD patients. This study shows the clinical significance of the VWFpp assay; it is of added value for the classification of VWD, for the assessment of the bleeding phenotype, for genetic counseling, and it also has therapeutic consequences.
